EMBCEmbecta Corp.
Price
-66%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: safety
Quality strong, a flag to check, undemanding price, growth steady, the market undecided.
Charts
As reported to the SEC, without any scoring.
Embecta Corp. (EMBC) reported revenue of $272M in Q3 2026 (quarter ended Jun 30, 2026), down 8.1% from the same quarter a year earlier. That came with a gross margin of 56% and net income of $21M (7.8% of revenue). For the full year FY2025, revenue was $1.08B (−3.8% year on year) and net income $95M. The next results filing is expected around Nov 24, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 7, 2026Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results.Earnings release · press release
- Jul 31, 2026Consolidated Statement of Comprehensive Income.Material event (exhibits only) · press release
- May 15, 2026On May 15, 2026, Embecta Corp. (“embecta”) completed its previously announced acquisition (the “Transaction”) of all of the issued share capital of Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK-based innovator and manufacturer of medical devices and drug-delivery technologies.Acquisition or disposition completed · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Medical Instruments & Supplies
Ranks #3 of 21 by RyuScore